A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

Part of paid clinical trials in Fairfax, Virginia.

Sponsor
Crossbow Therapeutics, Inc.
Study ID
NCT07779798
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Solid Tumors
  • Recurrent or Progressive Glioblastoma
  • Relapse or Refractory Myeloid Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CBX-663 — DRUG
    Intravenous (I.V.) CBX-663

Study Details

This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recurrent or progressive GBM (Cohort C) (collectively called 'indication cohorts'). Participants aged ≥18 years are planned to be enrolled. CBX-663 will initially be investigated on a fixed dosing schedule. CBX-663 will be administered intravenously (IV) on Cycle 1 Day 1 (C1D1) and then once weekly (QW) in 21-day cycles. Participants will continue treatment with CBX-663 until unacceptable toxicity, progressive disease, withdrawal of consent, or lack of clinical benefit.

Key Dates

First listed
Aug 21, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Jan 31, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CBX-663
    Intravenous (I.V.) CBX-663

Primary Outcome Measure

Recommended Phase 2 Dose (RP2D) [ Time Frame: Until the end of study (approximately 24 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
NEXT Oncology- VirginiaFairfaxVirginia22031
Maybelle De La Rosa
[email protected]
703-783-4518
Alexander Spira, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Fairfax, VA

By research site
NEXT Oncology- Virginia· Fairfax, VA

Related Studies